IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v44y1998i3p253-260.html
   My bibliography  Save this article

What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

Author

Listed:
  • Schneeweiss, Sebastian
  • Schoffski, Oliver
  • Selke, Gisbert W

Abstract

No abstract is available for this item.

Suggested Citation

  • Schneeweiss, Sebastian & Schoffski, Oliver & Selke, Gisbert W, 1998. "What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?," Health Policy, Elsevier, vol. 44(3), pages 253-260, June.
    • Handle: RePEc:eee:hepoli:v:44:y:1998:i:3:p:253-260
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(98)00023-2
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Ljungkvist, Mats-Olof & Andersson, David & Gunnarsson, Bo, 1997. "Cost and utilisation of pharmaceuticals in Sweden," Health Policy, Elsevier, vol. 41(Supplemen), pages 55-69, September.
    2. von der Schulenburg, J. -Matthias Graf, 1997. "Management of cost and utilization of pharmaceuticals in Germany," Health Policy, Elsevier, vol. 41(Supplemen), pages 45-53, September.
    3. Anonymous, 1990. "Editor's Report, 1990," Journal of Agricultural and Applied Economics, Cambridge University Press, vol. 22(1), pages 221-223, July.
    4. Abel-Smith, Brian & Mossialos, Elias, 1994. "Cost containment and health care reform: a study of the European Union," Health Policy, Elsevier, vol. 28(2), pages 89-132, May.
    5. Kane, Nancy M. & Saltman, Richard B., 1997. "Comparative experience in home care and pharmaceutical policy," Health Policy, Elsevier, vol. 41(Supplemen), pages 1-7, September.
    6. Kane, Nancy M., 1997. "Pharmaceutical cost containment and innovation in the United States," Health Policy, Elsevier, vol. 41(Supplemen), pages 71-89, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    2. Bergstrom, Gina & Karlberg, Ingvar, 2007. "Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective," Health Policy, Elsevier, vol. 81(2-3), pages 358-367, May.
    3. Busse, Reinhard, 1999. "Priority-setting and rationing in German health care," Health Policy, Elsevier, vol. 50(1-2), pages 71-90, December.
    4. Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B., 2001. "On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective," Health Policy, Elsevier, vol. 55(2), pages 97-109, February.
    5. Fabiano, Valentina & Mameli, Chiara & Cattaneo, Dario & Delle Fave, Antonella & Preziosa, Alessandra & Mele, Giuseppe & Clementi, Emilio & Zuccotti, Gian Vincenzo, 2012. "Perceptions and patterns of use of generic drugs among Italian Family Pediatricians: First round results of a web survey," Health Policy, Elsevier, vol. 104(3), pages 247-252.
    6. Andersson, Karolina & Bergstrom, Gina & Petzold, Max G. & Carlsten, Anders, 2007. "Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals," Health Policy, Elsevier, vol. 81(2-3), pages 376-384, May.
    7. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    8. Schneeweiss, Sebastian, 2007. "Reference drug programs: Effectiveness and policy implications," Health Policy, Elsevier, vol. 81(1), pages 17-28, April.
    9. Garattini, Livio & Tediosi, Fabrizio, 2000. "A comparative analysis of generics markets in five European countries," Health Policy, Elsevier, vol. 51(3), pages 149-162, April.
    10. Schreyögg, Jonas & Henke, Klaus-Dirk & Busse, Reinhard, 2004. "Managing pharmaceutical regulation in Germany: Overview and economic assessment," Discussion Papers 2004/6, Technische Universität Berlin, School of Economics and Management.
    11. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bergstrom, Gina & Karlberg, Ingvar, 2007. "Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective," Health Policy, Elsevier, vol. 81(2-3), pages 358-367, May.
    2. Gevers, J.M.P. & Gelissen, J.P.T.M. & Arts, W.A. & Muffels, R.J.A., 1999. "Public health care in balance : Exploring popular support for health care systems in the European Union," WORC Paper 99.12.04, Tilburg University, Work and Organization Research Centre.
    3. Grazyna Kozun-Cieslak & Pavel Zdrazil, 2021. "Efficiency of Healthcare Systems in the European Union States – Who Performs Better – Bismarckians or Beveridgeans?," European Research Studies Journal, European Research Studies Journal, vol. 0(Special 2), pages 397-411.
    4. Sarracino, Francesco & O'Connor, Kelsey J. & Ono, Hiroshi, 2019. "Making economic growth and well-being compatible: evidence from Japan," MPRA Paper 93010, University Library of Munich, Germany.
    5. Blazej Lyszczarz, 2016. "The effect of health care model on health systems' responses to economic crises," Ekonomia i Prawo, Uniwersytet Mikolaja Kopernika, vol. 15(4), pages 493-501, December.
    6. Matthieu Crozet & Laura Hering & Sandra Poncet, 2018. "Looking for the Bright Side of the China Syndrome: Rising Export Opportunities and Life Satisfaction in China," Working Papers 2018-14, CEPII research center.
    7. Donald Vandegrift & Anusua Datta, 2006. "Prescription Drug Expenditures in the United States: The Effects of Obesity, Demographics, and New Pharmaceutical Products," Southern Economic Journal, John Wiley & Sons, vol. 73(2), pages 515-529, October.
    8. Prosser, Helen & Walley, Tom, 2005. "A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing," Social Science & Medicine, Elsevier, vol. 60(6), pages 1335-1346, March.
    9. Ravi Kanbur, 2004. "Growth, Inequality And Poverty: Some Hard Questions," Working Papers 157, Institute for Social and Economic Change, Bangalore.
    10. repec:jtr:journl:v:9:y:2014:i:1:p:159-173 is not listed on IDEAS
    11. Francesco Sarracino & Kelsey J. O’Connor, 2021. "Economic growth and well-being beyond the Easterlin paradox," Chapters, in: Luigino Bruni & Alessandra Smerilli & Dalila De Rosa (ed.), A Modern Guide to the Economics of Happiness, chapter 9, pages 162-188, Edward Elgar Publishing.
    12. Schreyögg, Jonas & Henke, Klaus-Dirk & Busse, Reinhard, 2004. "Managing pharmaceutical regulation in Germany: Overview and economic assessment," Discussion Papers 2004/6, Technische Universität Berlin, School of Economics and Management.
    13. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    14. Mousnad, Mohamed Awad & Shafie, Asrul Akmal & Ibrahim, Mohamed Izham, 2014. "Systematic review of factors affecting pharmaceutical expenditures," Health Policy, Elsevier, vol. 116(2), pages 137-146.
    15. Liaropoulos, Lycurgus & Tragakes, Ellie, 1998. "Public/private financing in the Greek health care system: implications for equity," Health Policy, Elsevier, vol. 43(2), pages 153-169, February.
    16. Andrea Riganti, 2021. "Containing costs in the Italian local healthcare market," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1001-1014, May.
    17. Johnson, James D., 2002. "A Typology for U.S. Farms from National Survey Data," Workshop on the Farm Household-Firm Unit: Its Importance in Agriculture and Implications for Statistics, April 12-13,2002, Wye Campus, Imperial College 15725, International Agricultural Policy Reform and Adjustment Project (IAPRAP).
    18. Maurizio Pugno & Francesco Sarracino, 2021. "Structural Changes in Economic Growth and Well-Being: The Case of Italy’s Parabola," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 158(3), pages 801-838, December.
    19. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    20. Margaret Denton & Isik Zeytinoglu & Karen Kusch & Sharon Davies, 2007. "Market-Modelled Home Care: Impact on Job Satisfaction and Propensity to Leave," Canadian Public Policy, University of Toronto Press, vol. 33(s1), pages 81-99, January.
    21. Stargardt, Tom & Schreyögg, Jonas & Busse, Reinhard, 2007. "Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany," Health Policy, Elsevier, vol. 84(1), pages 30-38, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:44:y:1998:i:3:p:253-260. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.